Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Fiche publication
Date publication
mai 2023
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROYER Bernard
Tous les auteurs :
Royer B, Launay M, Ciccolini J, Derain L, Parant F, Thomas F, Guitton J
Lien Pubmed
Résumé
The chemotherapeutic agent 5-fluorouracil (5-FU) is catabolized by dihydropyrimidine dehydrogenase (DPD), the deficiency of which may lead to severe toxicity or death. Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens. However, it has been recently shown that renal impairment may impact uracil concentration and thus DPD phenotyping.
Mots clés
DPD phenotype, dihydropyrimidine dehydrogenase—DPD, fluoropyrimidine, multicentric study, renal impairment, uracil
Référence
ESMO Open. 2023 05 31;8(3):101577